Trial Profile
Biomarkers of Durable Response With Intermittent Therapy With LGX818 and MEK162 Combined Therapy in Patients With BRAF Mutant Metastatic Melanoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary) ; Encorafenib (Primary)
- Indications Liver metastases; Malignant melanoma
- Focus Therapeutic Use
- 20 Dec 2016 Status changed from recruiting to withdrawn prior to enrolment.
- 08 Jun 2016 Status changed from not yet recruiting to recruiting.
- 02 May 2016 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.